Journal: The FASEB Journal

Article Title: A self‐organized actomyosin drives multiple intercellular junction disruption and directly promotes neutrophil recruitment in lipopolysaccharide‐induced acute lung injury

doi: 10.1096/fj.201701506rr

Figure Lengend Snippet: Figure 2. Dynamic alterations of lung TJ and AJ, HUVEC permeability, and neutrophils after LPS administration in vivo and in vitro. E-cadherin (A, A9), VE-cadherin (B, B9), occludin (C, C0), CD11b (E, E9), and MPO (F, F9) staining and quantification of relative intensity or positive cells in 1 alveoli at 1, 3, 5, and 7 d after administration of LPS (15 mg/kg) or saline; and CD3, CD5, CD19, and CD45 staining (G) at 3 d after LPS treatment are shown. D) Double-labeling images are shown of occludin (red) with E-cadherin or VE-cadherin (green) and superimposition with DAPI (blue). H) Percentage of CD11b-, MPO-, CD3-, CD5-, CD19-, and CD45-positive cells in 1 alveoli. I) Levels of IL-6, IL-8, and TNF-a and MPO activity in the supernatants of human neutrophils at 1, 3, 5, 7, and 9 h after LPS (10 mg/ml) treatment are shown. J) HUVEC monolayer permeability, as reflected by FITC-albumin fluorescence intensity, was analyzed at 1, 3, 5, 7, and 9 h after treatment of LPS alone or LPS + neutrophil supernatants (LPS + S). Values are expressed as the means 6 SE; n = 3 (I, J); n = 10–13 alveoli from 3 mice (A2C9, E9,F9, H). Scale bars: 5 mm (D); 30 mm (A–C. E–G). N.S., no significant difference. **P , 0.01 compared with the control group, ##P , 0.01 compared with LPS group at 1 h.

Article Snippet: CD3, CD5, and CD45 antibodies were purchased from Proteintech Group (Rosemont, IL, USA).

Techniques: Permeability, In Vivo, In Vitro, Staining, Saline, Labeling, Activity Assay, Control

Journal: Experimental and Therapeutic Medicine

Article Title: Reduced inflammatory cell recruitment and tissue damage in spinal cord injury by acellular spinal cord scaffold seeded with mesenchymal stem cells

doi: 10.3892/etm.2016.3941

Figure Lengend Snippet: Quantitative comparison of the number of positive cells per field for (A) macrophages (CD68) and (B) T lymphocytes (CD5) showing significant differences for the BMSCs + ASC group compared with the ASC group (*P<0.05) and control group ( # P<0.05) at 2 weeks after surgery. (C) IgM shows no significant difference (P>0.05) among the groups. ASC, acellular spinal cord; BMSCs, bone marrow stromal cells; IgM, immunoglobulin M.

Article Snippet: Fluorescein isothiocyanate-labeled primary antibodies against immunoglobulin M (FITC anti-rat IgM; dilution, 1:100; cat. no. RUO 400801; BioLegend, Inc., San Diego, CA, USA), macrophages (anti-CD68/FITC; 100 µg; dilution, 1:100; cat. no. BS-0649R; Bioss, Inc., Woburn, MA, USA), and T lymphocytes (anti-CD5/FITC; dilution, 1:100; cat. no. BS-10218R; Bioss, Inc.) were used to evaluate each section.

Techniques: